Effective Strategies to Manage Hyperglycemia When Treating with PI3K and AKT Inhibitors

Program Description

Effective management and prevention of hyperglycemia are critical for patients with breast cancer undergoing treatment with PI3K and AKT inhibitors. This webinar will provide oncology pharmacists with proactive strategies to mitigate these risks and identify key risk factors that predispose patients to this adverse effect. A key focus of the program will be on the challenges and considerations in selecting appropriate antihyperglycemic therapies, such as metformin, sodium glucose co-transporter 2 (SGLT2) inhibitors, and other lifestyle interventions. Given that the PI3K/AKT pathway is a central target for both cancer and glucose metabolism, certain antidiabetes medications may present unique considerations and interactions with anticancer drugs that oncology pharmacists must advise upon within the interprofessional health care team. Throughout the webinar, opportunities for oncology pharmacists to engage in interventions in both the preventative and management settings, including the development of monitoring protocols to ensure patients with breast cancer can remain on their therapies with minimal metabolic complications, will be emphasized.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: November 7, 2025
Expiration date: November 7, 2026
Learner level: Intermediate
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Identify key risk factors for hyperglycemia in patients receiving PI3K and AKT inhibitors
• Explore evidence-based prevention strategies for hyperglycemia, including pharmacologic options and lifestyle interventions
• Express the challenges and considerations in selecting antihyperglycemic therapies for patients treated with PI3K or AKT inhibitors
• Show how oncology pharmacists can lead and support proactive interventions in both prevention and management settings to improve outcomes for patients at risk of or experiencing treatment-induced hyperglycemia

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-362-H05-P. The activity is available for CE credit through November 7, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Megan May, PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Speakers Bureau: Amgen, AstraZenca

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms